Search
Regeneron Pharmaceuticals Inc
REGNAdd to Watchlist
618.030USD
+5.530+0.90%
Close 06/23, 16:00（ET）Quotes delayed by 15 min
64.89BMarket Cap
14.55P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+0.90%
5 Days
+0.50%
1 Month
-3.26%
6 Months
-21.29%
Year to Date
-19.93%
1 Year
+21.25%
Key Figures
607.920Open
621.790High
1.28MVolume
14.55P/E TTM
10.94P/E Dynamic
3.580Dividend TTM
1.22%Turnover Ratio
612.500Prev. Close
607.920Low
664.30MTurnover
14.71P/E Static
2.07P/B
0.58%Div Yield TTM
11.40%ROA
821.11052wk High
0.87Volume Ratio
4.41BNet Profit
105.00MShares
42.4810EPS TTM
0.26Beta
14.69%ROE
476.48752wk Low
2.26%Amplitude
81.43%Gross Margin
64.89BMarket Cap
-2.37Reward/Risk
1.74%Risk Rate
TradingKey Stock Score of Regeneron Pharmaceuticals Inc
Currency: USD Updated: 2026-06-22Key Insights
Regeneron Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 16 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 830.43.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Regeneron Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
40°C
Very Low
Very High
Negative
Regeneron Pharmaceuticals Inc Highlights
StrengthsRisks
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
Undervalued
The company’s latest PE is 14.42, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 94.67M shares, decreasing 1.74% quarter-over-quarter.
Held by Mason Hawkins
Star Investor Mason Hawkins holds 160.58K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.31.
Analyst Rating
Based on
32
analysts
Buy
Current Rating
830.429
Target Price
+35.58%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Regeneron Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Regeneron Pharmaceuticals Inc Info
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
Ticker SymbolREGN
CompanyRegeneron Pharmaceuticals Inc
CEOSchleifer (Leonard S)
Websitehttps://www.regeneron.com/
Related Instruments
+0.54%
+3.37%
+2.60%
+2.07%
+3.54%
+2.98%
+0.66%
+3.33%
+0.14%
-1.44%
+0.32%
+1.53%
+2.59%
-0.36%
+2.58%
0.00%
+2.77%
-5.50%
+2.33%Popular Instruments
72.812
-0.133 (-0.18%)
294.300
-2.710 (-0.91%)
200.040
-8.610 (-4.13%)
4099.880
-10.870 (-0.26%)
670.750
-61.870 (-8.45%)
1961.070
-312.660 (-13.75%)
1051.770
-159.610 (-13.18%)
346.130
-3.550 (-1.02%)
62535.350
+94.650 (+0.15%)
381.610
-23.440 (-5.79%)
FAQs
What is the current price of Regeneron Pharmaceuticals Inc (REGN)?
The current price of Regeneron Pharmaceuticals Inc (REGN) is 612.45.
What is the symbol of Regeneron Pharmaceuticals Inc?
The ticker symbol of Regeneron Pharmaceuticals Inc is REGN.
What is the 52-week high of Regeneron Pharmaceuticals Inc?
The 52-week high of Regeneron Pharmaceuticals Inc is 821.11.
What is the 52-week low of Regeneron Pharmaceuticals Inc?
The 52-week low of Regeneron Pharmaceuticals Inc is 476.49.
What is the market capitalization of Regeneron Pharmaceuticals Inc?
The market capitalization of Regeneron Pharmaceuticals Inc is 64.21B.
Is Regeneron Pharmaceuticals Inc (REGN) currently rated as Buy, Hold, or Sell?
According to analysts, Regeneron Pharmaceuticals Inc (REGN) has an overall rating of Buy, with a price target of 830.43.
What is the Earnings Per Share (EPS TTM) of Regeneron Pharmaceuticals Inc (REGN)?
The Earnings Per Share (EPS TTM) of Regeneron Pharmaceuticals Inc (REGN) is 43.07.
